This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Clostridium Difficile Vaccine
Stellar Biotechnologies, Inc.
Drug Names(s): KLH-Conjugate Vaccine, PS-KLH
Description: Clostridium Difficile Vaccine is being developed using Stellar's K Keyhole Limpet Hemocyanin (KLH)-based combinatorial adjuvant technology.
Deal Structure: In April 2012, Stellar announced that it entered into an areement with the University of Guelph (Canada) for the exclusive option to license technology for the development of a vaccine candidate against Clostridium difficile infection (CDI).
Partners: University of Guelph
Clostridium Difficile Vaccine News
Additional information available to subscribers only: